Analysis of short-term efficacy of taxane based neoadjuvant chemotherapy in HER-2 positive breast cancer

doi:10.3877/cma. j. issn.1674-0807.2012.03.006

Abstract

Abstract:

Objective

To investigate the chemosensitivity of HER-2 positive advanced breast cancer patients treated with taxane.

Methods

The efficiency of neoadjuvant chemotherapy in 159 patients with HER-2 positive breast cancer was retrospectively analyzed. Chi-square test was used to compare pathological complete response(pCR) rate and the effective rate of chemotherapy between anthracycline-based chemotherapy group and taxane-based chemotherapy group.

Results

pCR rate was 7.4% in anthracycline-based group, significantly higher than 25.6% in taxane-based group(χ² =9.658,P=0.002). The effective rate of chemotherapy was 85.2% in anthracycline-based group,80.8% in taxane-based group, and no statistical difference was presented (χ² =0.550,P = 0.458).

Conclusion

For the patients with HER-2 positive breast cancer,taxane-based chemotherapy regimen can achieve a better PCR rate.

Key words: HER-2, breast neoplasms, taxoid, neoadjuvant chemotherapy

Zhi-hua LI, Chun-wei XIE, Yu GONG, Qiu-mo LEI. Analysis of short-term efficacy of taxane based neoadjuvant chemotherapy in HER-2 positive breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2012, 06(03): 272-278.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2012.03.006

https://zhrxbzz.cma-cmc.com.cn/EN/Y2012/V06/I03/272

Figures/Tables 6

References 16

[1]	张建会.HER-2 与乳腺癌关系的研究[J].中国医学检验杂志.2009,10(6):379-382.
[2]	Gutierrez C, Schiff R. HER-2: biology, detection, and clinical implications[J]. Arch Pathol Lab Med,2011,135(1):55-62.
[3]	张小平,陶永辉,陈其亮,等. 人乳腺癌细胞MCF-7 紫杉醇耐药株的建立及其生物学特性研究[J].中国药理学通报,2008,24(6):804-809.
[4]	李燕,王永华,房华,等.紫杉醇类衍生物的定量结构-抗癌活性关系研究进展[J].中国药理学通报,2008,24(3):288-293.
[5]	Kamil M, Yusuf N,Khalid I,et al. Association between HER-2/ neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia [J]. Ceylon Med J,2010,55(1):9-13.
[6]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2007 版) [J].中国癌症杂志,2007,17(5):410-428.
[7]	Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009,45(2):228-247.
[8]	代志军,王西京,李宗芳,等. HER-2 表达与乳腺癌不同方案新辅助化疗疗效的关系[J].南方医科大学学报,2007,27(9):1397-1399.
[9]	Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 trial[J]. J Clin Oncol,2009,27(8):1168-1176.
[10]	师以康,张胜华,黄云虹,等. 乳腺癌细胞的HER2 过表达降低其对紫杉醇的药物敏感性[J]. 中国药理学通报,2009,25(4):444-448.
[11]	刘尧,刘文超,陶玉荣.HER-2 过表达与乳腺癌治疗的相关性研究进展[J].现代肿瘤医学,2010,18(1):182-184.
[12]	Gajria D, Seidman A, Dang C. Adjuvant taxanes: more to the story [J]. Clin Breast Cancer,2010,(Suppl 2):S41-S49.
[13]	Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18[J]. Cancer,2002,95(4):681-695.
[14]	Darb-Esfahani S,Loibl S,Müller BM,et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER-2 receptor expression in patients treated with neoadjuvant/taxanebased chemotherapy [J]. Breast Cancer Res,2009,11(5):R69.
[15]	林本耀.乳腺癌[M].北京:中国医药科技出版社,2006:263-264.
[16]	张弛,段学宁.乳腺癌生物标记物表达水平对新辅助化疗疗效的预测价值[J/CD].中华乳腺病杂志:电子版,2010,4(6):712-720.

分组	例数	年龄(岁)	临床分期(例)		病理组织学类型(例)		ER/PR状态(例)
分组	例数	年龄(岁)	Ⅱ_B	Ⅲ	浸润性导管癌	非浸润性导管癌	阳性	阴性
蒽环组	81	47.5±9.0	52	29	72	9	49	32
紫杉组	78	46.3±8.3	50	28	71	7	51	27
统计量		0.901	0.000		0.200		0.407
P值		0.369	0.990		0.654		0.523

分组	例数	年龄(岁)	临床分期(例)		病理组织学类型(例)		ER/PR状态(例)
分组	例数	年龄(岁)	Ⅱ_B	Ⅲ	浸润性导管癌	非浸润性导管癌	阳性	阴性
蒽环组	81	47.5±9.0	52	29	72	9	49	32
紫杉组	78	46.3±8.3	50	28	71	7	51	27
统计量		0.901	0.000		0.200		0.407
P值		0.369	0.990		0.654		0.523

分组	例数	疗效[例(%)]		病理完全缓解情况[例(%)]
分组	例数	CR+PR	SD+PD	pCR	PINV
蒽环组	81	69(85.2)	12(14.8)	6(7.4)	75(92.6)
紫杉组	78	63(80.8)	15(19.2)	20(25.6)	58(74.4)
χ ²值		0.550		9.658
P值		0.458		0.002

分组	例数	疗效[例(%)]		病理完全缓解情况[例(%)]
分组	例数	CR+PR	SD+PD	pCR	PINV
蒽环组	81	69(85.2)	12(14.8)	6(7.4)	75(92.6)
紫杉组	78	63(80.8)	15(19.2)	20(25.6)	58(74.4)
χ ²值		0.550		9.658
P值		0.458		0.002

Please choose a citation manager

Content to export